

UBS Future of Humans USD F-acc

Fund Fact Sheet

UBS Funds for discretionary mandates > UBS Equity Funds

Fund description

- An actively managed multi-manager global equity fund that invests in companies exposed to the global trends toward an aging population, the growth in population and increasing urbanization.
- These aspects can comprise any sectors, countries and company capitalisations in order to benefit from disruptive developments in society, resources and technology, with a focus on longevity, education, healthcare and consumer preferences.

For further information, please see the Key Investor Information Document (KIID) available at: www.ubs.com/espanafondos.

Name of fund	Multi Manager Access II - Future of
	Humans
Share class	Multi Manager Access II - Future of
	Humans USD F-acc
ISIN	LU2213664688
Bloomberg	n.a.
Currency of fund / share	e class USD/USD
Launch date	19.10.2020
Issue/redemption	daily
Swing pricing	yes
Accounting year end	31 July
Benchmark	MSCI ACWI Net Total Return index
Distribution	Reinvestment
Management fee p.a.	0.65%
Entry charge (max.)	3.00%
Exit charge (max.)	0.00%
Conversion fee (max.)	3.00%
Performance fee	-%
Ongoing charges p.a. ¹	0.80%
Name of the	UBS Fund Management
Management Company	(Luxembourg) S.A.,
	Luxembourg
Fund domicile	Luxembourg
1 as at 19.02.2021	

	Lower	risk				Highe	er risk	_
	Typical	ly lower rewa	rds		Typica	ılly higher rev	wards	_
	1	2	3	4	5	6	7	
A cated	A category 1 rating should not be construed as indicating that the investment is free of any risk.				_			

Performance (basis USD, net of fees)1

The performance chart will be available 12 months after the fund's establishment.

in %	1 year	2 years	3 years	Ø p.a. 2	Ø p.a. 3
				years	years
Fund (USD)	n.a.	n.a.	n.a.	n.a.	n.a.
Ref. Index ²	n.a.	n.a.	n.a.	n.a.	n.a.
The performance shown does not take account of any commissions, entry or exit					

charges.

Fund statistics

Net asset value (USD, 31.08.2021)	120.65
Last 12 months (USD) – high	120.65
– low	93.98
Total fund assets (USD m)	1 092.53
Share class assets (USD m)	719.68

	3 years	5 years
Beta	n.a.	n.a.
Volatility ¹		_
– Fund	n.a.	n.a.
– Benchmark	n.a.	n.a.
Sharpe ratio	n.a.	n.a.
Risk free rate	n.a.	n.a.

Annualised standard deviation

For more information

Internet: www.ubs.com/luxembourgfunds Contact your client advisor

Before making any investment decisions, we recommend that you read the Key Investor Information Document (KIID) and Prospectus, which are available at: www.ubs.com/espanafondos.

<sup>These figures refer to the past. If the currency of a financial product or financial service is different from your reference currency, the return can increase or decrease as a result of currency fluctuations. Source for all data and charts (if not indicated otherwise): UBS Asset Management.
Reference Index in currency of share class (without costs)</sup>

UBS Future of Humans USD F-acc

Sector exposure (%)

sector exposure (70)				
	Fund	Index		
Health Care	59.89	11.84		
Consumer Discretionary	13.08	12.16		
Information Technology	8.83	22.63		
Financials	8.65	14.10		
Real estate	2.85	2.63		
Materials	1.76	4.86		
Consumer Staples	1.67	6.76		
Communication Services	1.53	9.43		
Industrials	0.92	9.80		
Others	0.82	5.79		

10 largest equity positions (%)

	Fund	Index
Abbott Laboratories	3.55	0.33
Medtronic PLC	2.82	0.26
Roche Holding AG	2.46	0.41
Novo Nordisk A/S	2.25	0.25
UnitedHealth Group Inc	2.05	0.58
Moderna Inc	2.03	0.17
Johnson & Johnson	2.01	0.67
AIA Group Ltd	1.96	0.21
Danaher Corp	1.92	0.30
AstraZeneca PLC	1.90	0.26

Market exposure (%)

•	-		
	Fund	Deviation from	n index
United States	55.94	-3.9	
Switzerland	8.08		+5.5
United Kingdom	6.94		+3.3
China	4.89		1 +0.8
Ireland	3.79		+3.6
Denmark	3.38		+2.7

	Fund	Deviation from index
Japan	3.12	-2.7
Germany	2.93	I +0.6
Hong Kong	2.59	■ +1.8
France	1.60	-1.3 ■
Others	6.74	-10.4

Benefits

Benefit from developments driven by the meta themes education, healthcare and changing consumer preferences. Harnesses the dedicated capabilities of leading thematic portfolio managers, most of whom are not accessible via public funds.

A focus on attractively valued companies with strong links to the respective themes.

The structure allows for the addition/removal of managers as well as portfolio optimization.

Risks

A new fund with no track record, notwithstanding the investment history of the portfolio managers. An equity fund with exposure to small, growing and innovative companies which can result in significant fluctuations in value, particularly in the short term. The thematic focus may lead to concentrations in a specific sector or style.

The performance of actively managed funds may deviate significantly from the referenced index.

The fund can use derivatives, which may result in additional counterparty and liquidity risks.

Please note that additional fees (e.g. entry or exit fees) may be charged. Please refer to your financial adviser for more details. Investors should read the Key Investor Information Document (KIID), Prospectus and any applicable local offering document prior to investing. For a definition of financial terms refer to the glossary available at www.ubs.com/amglossary.

For marketing and information purposes by UBS. UBS funds under Luxembourg law. Arrangements for marketing fund units mentioned in this document may be terminated at the initiative of the management company of the fund(s). CMMV registration number: . Representative in Spain for UBS funds established under foreign law: UBS Europe SE, sucursal en España, MARÍA DE MOLINA, 4, E-28006 MADRID. Prospectuses, key investor information (KIID), the articles of association or the management regulations as well as annual and semi-annual reports of UBS funds are available in a language required by the local applicable law free of charge from UBS Europe SE, sucursal en España, MARÍA DE MOLINA N° 4, E-28006 MADRID / AVENIDA DIAGONAL N° 640, 2° A, E-08017 BARCELONA / FERNÁNDEZ Y GONZÁLEZ N° 2, PLANTA PRINCIPAL, E-41001 SEVILLA / C/ROGER DE LAURIA N° 7, 1° PLANTA, E-46002 VALENCIA / COSO N° 33, 5° A, E-50003 ZARAGOZA, CANTÓN PEQUEÑO 15, 4°, E-15003 A CORUÑA and online at www.ubs.com/funds. The product described herein aligns to Article 6 of Regulation (EU) 2019/2088. Before investing in a product please read the latest prospectus and key investor information document carefully and thoroughly. The fund documentation is available free of charge in English and, where relevant, in one of the local language(s) where the fund is registered. The information and opinions contained in this document have been compiled or arrived at based upon information obtained from sources believed to be reliable and in good faith, but is not guaranteed as being accurate, nor is it a complete statement or summary of the securities, markets or developments referred to in the document. Members of the UBS Group may have a position in and may make a purchase and / or sale of any of the securities, markets or developments referred to in the document. Units of UBS funds mentioned herein may not be eligible for sale in all jurisdictions or to certain categories of investors and may not be offered, sold or delivered in the United States. The information mention